Ovarian cancer vaccine trial: could your own tumor train your body to fight back?
NCT ID NCT05773859
First seen Nov 18, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This early-phase trial tests a personalized vaccine made from a patient's own tumor cells. The vaccine is designed to train the immune system to recognize and attack ovarian cancer. The study involves 10 women with advanced ovarian cancer who will receive the vaccine alongside standard chemotherapy. The main goal is to see if the vaccine triggers an immune response and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Radboud University Medical Center
RECRUITINGNijmegen, Gelderland, 6500 HB, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.